FGEN - FibroGen, Inc.

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by fireopal, Aug 9, 2017.

  1. fireopal

    fireopal Well-Known Member

    Joined:
    Apr 18, 2016
    Messages:
    2,271
    Likes Received:
    512
    [​IMG]
    FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

    Company site - http://www.fibrogen.com

    OS = 5 69.94M
    Float + 64.9M
    Insiders = 18.93%
    Institutions = 1 42.30%

    FibroGen shares surge 49% on positive mid-stage trial for pulmonary fibrosis therapy - http://www.marketwatch.com/story/fi...s-therapy-2017-08-08?siteid=yhoof2&yptr=yahoo
     
  2. fireopal

    fireopal Well-Known Member

    Joined:
    Apr 18, 2016
    Messages:
    2,271
    Likes Received:
    512
    Good short?
     
  3. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    8,235
    Likes Received:
    2,892
  4. StockJock-e

    StockJock-e Brew Master
    Staff Member

    Joined:
    Apr 3, 2016
    Messages:
    8,235
    Likes Received:
    2,892
    What happened

    Shares of FibroGen (NASDAQ:FGEN) were crashing 37.8% lower as of 10:45 a.m. EDT on Wednesday. The huge drop came after the company announced a stunning revelation following the market close on Tuesday. FibroGen revealed that some previously disclosed safety analyses from a late-stage study of roxadustat in treating anemia of chronic kidney disease (CKD) were incorrect.
     
  5. T0rm3nted

    T0rm3nted Moderator
    Staff Member

    Joined:
    Apr 2, 2016
    Messages:
    7,947
    Likes Received:
    2,881
    Dishonesty in the biopharm industry? Who would have thunk?
     

Share This Page